Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

It would take the legal exposure off the table relating to MNTA and have a viable biosimilar program with a partner in place.

Two points that argue against such a scenario:

1. WPI’s acquiring MNTA would not necessarily remove WPI’s legal liability for the Lovenox launch. Insofar as there are two plaintiffs and two defendants in this litigation, it’s hard to say how such a transaction would affect the ultimate damage awards in the case.

2. WPI already has an FoB collaboration with AMGN (#msg-70097496).

Regards, Dew